{"id":"NCT00988429","sponsor":"Bial - Portela C S.A.","briefTitle":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures","officialTitle":"Efficacy and Safety of Eslicarbazepine Acetate (BIA 2-093) as Adjunctive Therapy for Refractory Partial Seizures in a Double-blind, Randomised, Placebo-controlled, Parallel-group, Multicentre Trial","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-12-02","primaryCompletion":"2012-01-12","completion":"2012-01-12","firstPosted":"2009-10-02","resultsPosted":"2014-04-15","lastUpdate":"2021-05-19"},"enrollment":653,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Partial Epilepsy"],"interventions":[{"type":"DRUG","name":"800 mg QD Eslicarbazepine acetate","otherNames":["BIA 2-093"]},{"type":"DRUG","name":"1200 mg QD Eslicarbazepine acetate","otherNames":["BIA 2-093"]},{"type":"DRUG","name":"Placebo","otherNames":["Sugar pills"]}],"arms":[{"label":"800 mg QD Eslicarbazepine acetate","type":"ACTIVE_COMPARATOR"},{"label":"1200 mg QD Eslicarbazepine acetate","type":"ACTIVE_COMPARATOR"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to determine whether Eslicarbazepine acetate (BIA 2-093) is an effective adjunct therapy in the treatment of refractory partial seizures","primaryOutcome":{"measure":"Seizure Frequency Over the 12-week Maintenance Period.","timeFrame":"12-week maintenance period (Week 3 to week 14)","effectByArm":[{"arm":"Placebo (ITT Population)","deltaMin":7.88,"sd":0.49},{"arm":"ESL 800 mg QD (ITT Population)","deltaMin":6.54,"sd":0.41},{"arm":"ESL 1200 mg QD (ITT Population)","deltaMin":6,"sd":0.4}],"pValues":[{"comp":"OG000 vs OG001","p":"0.058"},{"comp":"OG000 vs OG002","p":"0.004"}]},"eligibility":{"minAge":"16 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":162,"countries":["United States","Argentina","Belgium","Brazil","Canada","Cyprus","France","Germany","Greece","Italy","Poland"]},"refs":{"pmids":["33338829","32801102"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":7,"n":224},"commonTop":["Dizziness","Somnolence","Headache","Nausea","Diplopia"]}}